• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » New US FDA guidance: Six benefit-risk factors to include in medical device IDE applications

New US FDA guidance: Six benefit-risk factors to include in medical device IDE applications

June 24, 2015 By MassDevice

New US FDA guidance: Six benefit-risk factors to include in medical device IDE applications

By Stewart Eisenhart, Emergo Group

In an effort to boost predictability and transparency of its Investigational Device Exemption (IDE) review process, the US Food and Drug Administration has published new guidance explaining key issues the agency uses to assess benefits and risks of IDE submissions for clinical investigations of Class III and some Class II medical devices.

The guidance explains how FDA reviewers apply risk-benefit considerations and frameworks to their IDE determinations, and how risk-benefit assessments play a different role in reviewing IDE applications than for Premarket Approval (PMA) and 510(k) premarket notification reviews.

Among the guidance’s components most pertinent to IDE applicants are FDA recommendations that clinical study sponsors include summaries of benefit-risk assessment issues in their submissions to the agency. Specifically, IDE applicants’ summaries should include the following six considerations:

  • Context of proposed investigation: which disease is being targeted, how does the device under investigation treat that disease, and what are the investigation’s objective and design?
  • Assessment of proposed investigation’s risks: What are the key risks involved in the investigation – risk characterization, control measures and residual risk?
  • Assessment of proposed investigation’s benefits: What are the investigation’s key benefits for study subjects and/or expanding clinical knowledge?
  • Patient preference information: What patient preference information, if any, exists?
  • Assessment of uncertainty: Which aspects of the proposed investigation and of available clinical evidence create the most uncertainty, and why is that level of uncertainty acceptable for the proposed investigation?
  • Conclusions: How do the issues identified in this summary justify granting the IDE request and conducting the investigation?

By including this information in their IDE applications, clinical investigation sponsors and/or medical device manufacturers would directly address many key questions FDA reviewers have when examining submissions, potentially speeding up IDE decisions and avoiding hold-ups.

The FDA is accepting comments on the new IDE guidance through mid-September 2015.

Stewart Eisenhart covers medical device regulatory affairs for Emergo Group.

The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.

Filed Under: Blog, Emerging Markets, Regulatory/Compliance Tagged With: Emergo Group, FDA

More recent news

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy